References

References:

1. Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th ed. New York,
NY: Garland Science; 2001.
2. Wolden-Kirk H, Overbergh L, Christesen HT, Brusgaard K, Mathieu C. Vitamin D and diabetes: its importance for betacell
and immune function. Mol Cell Endocrinol. 2011;347(1-2):106-120.
3. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98-107.
4. Brooks-Worrell B, Palmer JP. Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet
autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin Exp Immunol.
2012;167:40-46.
5. Imai Y, Dobrain AD, Morris MA, Nadler JL. Islet inflammation: a unifying target for diabetes treatment? Trends Endocrinol
Metab. 2013;24(7):351-360.
6. Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms
and implications for the prevention and treatment of disease. Nat Rev Immunol. 2011;11(9):607-615.
7. Eizirik DL, Miani M, Cardozo AK. Signalling danger: endoplasmic reticulum stress and the unfolded protein response in
pancreatic islet inflammation. Diabetologia. 2013;56(2):234-241.
8. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720-3732.
9. Herder C, Brunner EJ, Rathmann W, et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede
the onset of type 2 diabetes: the Whitehall II study. Diabetes Care. 2009;32:421-423.
10. Green-Mitchell SM, Tersey SA, Cole BK, et al. Deletion of 12/15-lipoxygenase alters macrophage and islet function in
NOD-Alox15(null) mice, leading to protection against type 1 diabetes development. PLoS One. 2013;8(2):e56763.
11. Cole BK, Morris MA, Grzesik WJ, Leone KA, Nadler JL. Adipose tissue-specific deletion of 12/15-lipoxygenase protects mice
from the consequences of a high-fat diet. Mediators Inflamm. 2012;2012:851798.
12. Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type
2 diabetes. Diabetes Care. 2012;35(8):1654-1662.
13. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005;98(4):1154-1162.
14. Ellingsgaard H, Hauselmann I, Schuler B, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-
1 secretion from L cells and alpha cells. Nat Med. 2011;17(11):1481-1489.
15. Giarratana N, Penna G, Amuchastegui S, Mariani R, Daniel KC, Adorini L. A vitamin D analog down-regulates pro-inflammatory
chemokine production by pancreatic islets inhibiting T-cell recruitment and type 1 diabetes development. J
Immunol. 2004;173:2280-2287.
16. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events:
rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J.
2011;162:597-605.
17. Goldfine AB, Conlin PR, Halperin F, et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors
in persons with abnormal glucose tolerance. Diabetologia. 2013;56(4):714-723.
18. Ma K, Nunemaker CS, Wu R, Chakrabarti SK, Taylor-Fishwick DA, Nadler JL. 12-Lipoxygenase products reduce insulin
secretion and B-cell viability in human islets. J Clin Endocrinol Metab. 2010;95:887-893.
19. Weaver JR, Holman TR, Imai Y, et al. Integration of pro-inflammatory cytokines, 12-lipoxygenase and NOX-1 in pancreatic
islet beta-cell dysfunction. Mol Cell Endocrinol. 2012;358(1):88-95.

“Islet Inflammation”
I. General points on islet inflammation in diabetes
II. What are the actors in inflammation in diabetes?
III. Conclusion
References
Lectures during IGIS meeting